Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC

This trial is testing a combination of Toripalimab (an immunotherapy drug) and cryoablation (freezing tumors to destroy them) as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) whose cancer has begun to progress in a limited number of spots (called oligoprogression) after initial treatment. **You may be eligible if:** - You are 18–75 years old with confirmed stage IV non-small cell lung cancer - Your cancer has no driver gene mutations (EGFR, ALK, ROS1, etc.) - Your cancer has shown oligoprogression (1–5 metastatic spots in no more than 3 organs) after first-line therapy - You have good physical functioning (ECOG score 0–1) - You have at least one measurable tumor **You may NOT be eligible if:** - Your cancer has spread to the brain (active brain metastases) - You have a history of autoimmune disease requiring systemic immunosuppression - You have active liver disease, hepatitis, cirrhosis, or active tuberculosis - You are HIV positive - You have previously received targeted therapies for NSCLC - You are pregnant or received a live virus vaccine within 30 days of starting treatment Talk to your doctor to see if this trial is right for you.